Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults

Trial Profile

Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2013

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 12 Sep 2011 Results presented at the Fourth ESWI Influenza Conference, according to a Medicago media release.
    • 08 Jun 2011 Secondary endpoints 'Geometric-mean-antibody-titre' and 'Immunological-response-rate' have been met.
    • 06 Jun 2011 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top